Rice Hall James & Associates LLC Has $6.99 Million Holdings in Taysha Gene Therapies, Inc. $TSHA

Rice Hall James & Associates LLC boosted its position in shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA) by 119.8% during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 1,270,645 shares of the company’s stock after buying an additional 692,527 shares during the quarter. Rice Hall James & Associates LLC owned approximately 0.46% of Taysha Gene Therapies worth $6,989,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Marex Group plc acquired a new position in Taysha Gene Therapies during the 2nd quarter worth $29,000. E Fund Management Co. Ltd. acquired a new position in Taysha Gene Therapies during the 2nd quarter worth $31,000. Arrowpoint Investment Partners Singapore Pte. Ltd. acquired a new position in Taysha Gene Therapies during the 3rd quarter worth $40,000. Tower Research Capital LLC TRC lifted its holdings in Taysha Gene Therapies by 156.5% during the 2nd quarter. Tower Research Capital LLC TRC now owns 17,606 shares of the company’s stock worth $41,000 after buying an additional 10,742 shares in the last quarter. Finally, Caitong International Asset Management Co. Ltd lifted its holdings in Taysha Gene Therapies by 143.8% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 7,811 shares of the company’s stock worth $43,000 after buying an additional 4,607 shares in the last quarter. Institutional investors and hedge funds own 77.70% of the company’s stock.

Analyst Ratings Changes

Several research analysts have issued reports on TSHA shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Taysha Gene Therapies in a report on Friday, March 27th. Canaccord Genuity Group upped their price objective on Taysha Gene Therapies from $14.00 to $17.00 and gave the stock a “buy” rating in a report on Monday, April 6th. Chardan Capital reaffirmed a “buy” rating and set a $12.00 price objective on shares of Taysha Gene Therapies in a report on Thursday, March 19th. Needham & Company LLC upped their price objective on Taysha Gene Therapies from $10.00 to $12.00 and gave the stock a “buy” rating in a report on Thursday, March 19th. Finally, Truist Financial raised Taysha Gene Therapies to a “strong-buy” rating in a research note on Wednesday, March 25th. Two investment analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, Taysha Gene Therapies has an average rating of “Buy” and a consensus price target of $11.64.

Insider Buying and Selling

In related news, insider Sukumar Nagendran sold 200,000 shares of the firm’s stock in a transaction on Friday, April 10th. The stock was sold at an average price of $4.46, for a total transaction of $892,000.00. Following the sale, the insider owned 1,136,410 shares of the company’s stock, valued at approximately $5,068,388.60. This trade represents a 14.97% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 3.78% of the company’s stock.

Taysha Gene Therapies Stock Up 4.6%

Shares of NASDAQ TSHA opened at $5.97 on Tuesday. Taysha Gene Therapies, Inc. has a 52-week low of $2.25 and a 52-week high of $7.30. The company has a debt-to-equity ratio of 0.23, a quick ratio of 14.04 and a current ratio of 14.04. The stock has a market cap of $1.72 billion, a P/E ratio of -15.71 and a beta of 1.19. The firm has a 50 day moving average price of $5.80 and a 200 day moving average price of $5.19.

Taysha Gene Therapies (NASDAQ:TSHA) last posted its earnings results on Wednesday, May 6th. The company reported ($0.12) earnings per share for the quarter, missing the consensus estimate of ($0.10) by ($0.02). Analysts expect that Taysha Gene Therapies, Inc. will post -0.5 EPS for the current year.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc (NASDAQ: TSHA) is a clinical-stage biotechnology company focused on developing gene therapies for rare monogenic diseases of the central nervous system. Using a proprietary adeno-associated viral (AAV) vector platform, the company engineers novel capsids and regulatory elements to optimize delivery and expression of therapeutic genes. Its pipeline features lead programs such as TSHA-102 for GM2 gangliosidoses (Tay–Sachs and Sandhoff diseases), TSHA-101 for GM1 gangliosidosis and TSHA-103 for aromatic l-amino acid decarboxylase (AADC) deficiency, alongside earlier-stage candidates targeting other life-threatening pediatric CNS disorders.

Founded in 2019 and headquartered in Dallas, Texas, Taysha Gene Therapies completed its initial public offering in May 2021.